Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming

Posted May 06 2013 8:00pm

Description of Invention:
Five human induced pluripotent stem cells (iPSC) lines are generated using lentivirus-based reprogramming technology. These lines are pluripotent, meaning they have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely. The iPSC lines are: NC1 (derived from female's fibroblasts), NC2 (derived from female's fibroblasts ), NC3 (derived from male's HUVECS), NC4 (derived from male's fibroblasts) and NC5 (derived from female's fibroblasts). Further details of these cells are available upon request. NC1 uses a retrovirus delivery system incorporating the following vectors: pMIG-hKLF4, pMIG-hOCT4, pMIG-hSOX2, and MSCV h c-MYC IRES GFP. NC2-NC5 use the hSTEMCCA-loxP lentivirus delivery system (a gift from Dr. Gustavo Mostoslavsky). These cell lines will be useful for studies related to stem cell biology, understanding diseases, potential cell therapies, and small molecule screening.

Applications:
The iPSCs of this technology are useful:
  • to study the biology of stem cell development
  • as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases
  • to test different characterization and differentiation assays


Advantages:
  • These cells can serve as control cells and, thus, significantly reduce the cost of initiating many research projects.
  • These cells can be a good source of control cells.


Development Status:
  • Prototype
  • Pilot
  • Early-stage
  • In vitro data available


Inventors:
Manfred Boehm (NHLBI)
Guibin Chen (NHLBI)


Patent Status:
HHS, Reference No. E-274-2012/0

Research Tools – Patent protection is not being pursued for this technology.

Collaborative Research Opportunity:
The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Induced Pluripotent Stem Cells. For collaboration opportunities, please contact Denise Crooks at 301-435-0103.


For Licensing Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220


Ref No: 2558

Updated: 05/2013

Post a comment
Write a comment:

Related Searches